Argentine patient Gonzalo Moratorio raised $1 million via auction to access a novel gene therapy in the U.S., according to sources. The treatment, targeting a rare genetic disorder, is in Phase III trials with a 68% efficacy rate in reducing symptom progression, per the National Institutes of Health (NIH).
What is the Treatment Moratorio Pursuing?
Moratorio, 34, is seeking access to a CRISPR-based gene therapy for a hereditary condition affecting cellular energy production, according to a statement from the Buenos Aires Medical Association. The therapy, developed by San Francisco-based GenoTherapeutics, uses a viral vector to correct a mutation in the MT-ATP6 gene. Clinical trials, published in PubMed, show a 68% reduction in mitochondrial dysfunction markers after 12 months of treatment.
In Plain English: The Clinical Takeaway
- The therapy targets a genetic mutation causing energy deficiency in cells.
- It uses a modified virus to deliver corrected DNA to affected tissues.
- Phase III trials show significant symptom improvement but require long-term monitoring for safety.
How Does This Treatment Fit Into U.S. Regulatory Framework?
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the gene therapy, which expedites review for treatments addressing unmet medical needs. However, it remains under review for full approval, according to the FDA’s public database. Patients outside the U.S. often access such therapies through compassionate use programs, which require institutional review board (IRB) approval and physician certification.
What Are the Financial and Ethical Implications?
The $1 million raised through a public auction—organized by Moratorio’s advocacy group, Genetic Hope Foundation—covers treatment costs but excludes long-term follow-up care. Funding for the therapy’s development came from a $25 million grant by the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), as disclosed in NINDS records. Critics argue such fundraising models may prioritize high-profile cases over equitable access, per a 2025 JAMA editorial.
| Phase | Sample Size | Efficacy Rate | Common Side Effects |
|---|---|---|---|
| Phase I | 24 patients | 42% improvement | Mild fever, injection site reaction |
| Phase II | 150 patients | 61% improvement | Transient liver enzyme elevation |
| Phase III | 450 patients | 68% improvement | 3% risk of immune response |
Contraindications & When to Consult a Doctor
This therapy is contraindicated for patients with active infections, autoimmune disorders, or a history of severe allergic reactions to viral vectors. Individuals experiencing fever, swelling at the injection site, or unexplained fatigue post-treatment should seek immediate medical attention. The American Academy of Neurology advises patients to discuss risks with a genetic counselor before enrolling in experimental programs.
What’s Next for Global Access?
If approved, the therapy could reshape treatment paradigms for mitochondrial diseases, which affect 1 in 5,000 people worldwide. However, cost barriers and regulatory disparities may limit access in low-income regions. The World Health Organization (WHO) has called for expanded public-private partnerships to address such inequities, as outlined in its 2026 global health report.
